The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions

Refractory/Relapsed Autoimmune Hemolytic Anemia

Interventions

DRUG

Ibrutinib

Each recruited subject will accept Ibrutinib treatment.

Trial Locations (3)

Zhoukou Central Hospital, Zhoukou

The Second Affilated Hospital of Shandong First Medical University, Tai’an

Regenerative Medicine Center, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER